Association between metalloproteinases 2 and 9 activity and ERK1/2 phosphorylation status in head and neck cancers: An ex vivo study

Oncology Reports

Volumn 24, Issue 4, 2010, Pages 1073-1078

  Garavello, Werner ^a,b   Maggioni, Daniele ^a   Nicolini, Gabriella ^a   Motta, Lorenzo ^b   Tredici, Giovanni ^a   Gaini, Renato ^b  

^a UNIVERSITY OF MILANO BICOCCA   (Italy)

^b SAN GERARDO HOSPITAL   (Italy)

Author keywords

ERK; Head and neck squamous cell carcinoma; Metalloproteinase 2; Metalloproteinase 9

Indexed keywords

GELATIN; GELATINASE; GELATINASE A; GELATINASE B; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME PHOSPHORYLATION; EX VIVO STUDY; HEAD AND NECK CANCER; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOBLOTTING; PRIORITY JOURNAL; PROTEIN EXPRESSION; WESTERN BLOTTING; ZYMOGRAPHY;

ADULT; AGED; AGED, 80 AND OVER; BLOTTING, WESTERN; CARCINOMA, SQUAMOUS CELL; FEMALE; GENE EXPRESSION; GENE EXPRESSION REGULATION, NEOPLASTIC; HEAD AND NECK NEOPLASMS; HUMANS; MALE; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; MIDDLE AGED; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; PHOSPHORYLATION;

EID: 77957350003     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or-00000957     Document Type: Article

References (28)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J and Thun MJ: Cancer statistics, 2009. CA Cancer J Clin 59: 225-249, 2009.
2. Rogers SJ, Harrington KJ, Rhys-Evans P, O-Charoenrat P and Eccles SA: Biological significance of c-erb family oncogenes in head and neck. Cancer Metastasis Rev 24: 47-69, 2005.
3. Bogusiewicz M, Stryjecka-Zimmer M, Szymanski M, Rechberger T and Golabek W: Activity of matrix metalloproteinases- 2 and -9 in advanced laryngeal cancer. Otolaryngol Head Neck Surg 128: 132-136, 2003.
4. Gelse K, Pöschl E and Aigner T: Collagens-structure, function and biosynthesis. Adv Drug Deliv 55: 1531-1546, 2003.
5. Coussens LM, Tinkle CL, Hanahan D and Werb Z: MMP-9 supplied by bone marrow-derived cells contributes to skin carcinogenesis. Cell 103: 481-490, 2000.
6. Franchi A, Santucci M, Masini E, et al: Expression of matrix metalloproteinase 1, matrix metalloproteinase 2 and matrix metalloproteinase 9 in carcinoma of the head and neck. Cancer 95: 1902-1910, 2002.
7. Patel V, Ramesh A, Traicoff JL, Baibakov G, Emmert-Buck MR, Gutkind JS and Knezevic V: Profiling EGFR activity in head and neck squamous cell carcinoma by using a novel layered membrane Western blot technology. Oral Oncol 41: 503-508, 2005.
8. Christopoulos TA, Papageorgakopoulou N, Ravazoula P, Mastronikolis NS, Papadas TA, Theocharis DA and Wynios DH: Expression of metalloproteinases and their tissue inhibitors in squamous cell laryngeal carcinoma. Oncol Rep 18: 855-860, 2007.
9. Zhang S, Li Z, Wu X, Huang Q, Shen HM and Ong CN: Methyl- 3-indolylacetate inhibits cancer cell invasion by targeting the MEK1/2-ERK1/2 signaling pathway. Mol Cancer Ther 5: 3285-3293, 2006.
10. Mendes O, Kim HT, Lungu G and Stoica G: MMP2 role in breast cancer brain metastasis development and its regulation by TIMP2 and ERK1/2. Clin Exp Metastasis 24: 341-351, 2007.
11. Chang YM, Shih YT, Chen YS, Liu CL, Fang WK, Tsai CH, Tsai FJ, Kuo WW, Lai TY and Huang CY: Schwann cell migration induced by earthworm extract via activation of PAs and MMP2/9 mediated through ERK1/2 and p38. Evid Based Complement Alternat Med, March 20, 2010 (Epub ahead of print).
12. Mebratu Y and Tesfaigzi Y: How ERK1/2 activation controls cell proliferation and cell death: is subcellular localization the answer? Cell Cycle 8: 1168-1175, 2009.
13. Scuteri A, Galimberti A, Maggioni D, Ravasi M, Pasini S, Nicolini G, Bossi M, Miloso M, Cavaletti G and Tredici G: Role of MAPKs in platinum-induced neuronal apoptosis. Neurotoxicology 30: 312-319, 2009.
14. Owens DM and Keyse SM: Differential regulation of MAP kinase signaling by dual-specificity protein phosphatases. Oncogene 26: 3203-3213, 2007.
15. Katz M, Amit I and Yarden Y: Regulation of MAPKs by growth factors and receptor tyrosine kinases. Biochim Biophys Acta 1773: 1161-1176, 2007.
16. Montagut C and Settleman J: Targeting the RAF-MEK-ERK pathway in cancer therapy. Cancer Lett 283: 125-134, 2009.
17. Garavello W, Nicolini G, Aguzzi A, Maggioni D, Leone BE, Viganò P, Gaini RM and Tredici G: Selective reduction of extracellular signal-regulated protein kinase (ERK) phosphorylation in squamous cell carcinoma of the larynx. Oncol Rep 16: 479-484, 2006.
18. Aguzzi A, Maggioni D, Nicolini G, Tredici G, Gaini RM and Garavello W: MAP kinase modulation in squamous cell carcinoma of the oral cavity. Anticancer Res 29: 303-308, 2009.
19. Munshi HG, Wu YI, Mukhopadhyay S, Ottaviano AJ, Sassano A, Koblinski JE, Platanias LC and Stack MS: Differential regulation of membrane type 1-matrix metalloproteinase activity by ERK 1/2- and p38 MAPK-modulated tissue inhibitor of metalloproteinases 2 expression controls transforming growth factor-beta1-induced pericellular collagenolysis. J Biol Chem 279: 39042-39050, 2004.
20. Werner JA, Rathcke IO and Mandic R: The role of matrix metalloproteinases in squamous cell carcinomas of the head and neck. Clin Exp Metastasis 19: 275-282, 2002.
21. Rosenthal EL and Matrisian LM: Matrix metalloproteases in head and neck cancer. Head Neck 28: 639-648, 2006.
22. Yoshizaki T, Sato H and Furukawa M: Recent advances in the regulation of matrix metalloproteinase 2 activation: from basic research to clinical implication (Review). Oncol Rep 9: 607-611, 2002.
23. Bindhu OS, Ramadas K, Sebastian P and Pillai MR: High expression levels of nuclear factor kappa B and gelatinases in the tumorigenesis of oral squamous cell carcinoma. Head Neck 28: 916-925, 2006.
24. Kaomongkolgit R, Cheepsunthorn P, Pavasant P and Sanchavanakit N: Iron increases MMP-9 expression through activation of AP-1 via ERK/Akt pathway in human head and neck squamous carcinoma cells. Oral Oncol 44: 587-594, 2008.
25. Hammani K, Blakis A, Morsette D, Bowcock AM, Schmutte C, Henriet P and DeClerck YA: Structure and characterization of the human tissue inhibitor of metalloproteinases-2 gene. J Biol Chem 271: 25498-25505, 1996. (Pubitemid 26337925)
26. Raman M, Chen W and Cobb MH: Differential regulation and properties of MAPKs. Oncogene 26: 3100-3112, 2007.
27. Santen RJ, Song RX, McPherson R, Kumar R, Adam L, Jeng MH and Yue W: The role of mitogen-activated protein (MAP) kinase in breast cancer. J Steroid Biochem Mol Biol 80: 239-256, 2002.
28. Lee SH, Lee JW, Soung YH, Kim SY, Nam SW, Park WS, Kim SH, Yoo NJ and Lee JY: Colorectal tumors frequently express phosphorylated mitogen-activated protein kinase. APMIS 112: 233-238, 2004.